Title:
USE OF GINSENOSIDE RG2 IN PREPARATION OF DRUG FOR TREATING MYELOSUPPRESSION AND DRUG CONTAINING GINSENOSIDE RG2
Document Type and Number:
WIPO Patent Application WO/2022/257253
Kind Code:
A1
Abstract:
The use of ginsenoside Rg2 in the preparation of a drug for treating myelosuppression and a drug containing ginsenoside Rg2. When chemotherapy causes myelosuppression, the use of ginsenoside Rg2 can promote the recovery of the ingredients of bone marrow cells, increase the number of bone marrow nucleated cells, remarkably increase the number of granulocyte-monocyte colony forming units and pre-B colony forming units in bone marrow, and promote the proliferation of granulocyte-monocyte and pre-B hematopoietic progenitor cells, which indicates that the ginsenoside Rg2 has the effect of promoting medullary hematopoiesis.
Inventors:
FAN XIAOHUI (CN)
QIAN JING (CN)
QIAN JING (CN)
Application Number:
PCT/CN2021/109266
Publication Date:
December 15, 2022
Filing Date:
July 29, 2021
Export Citation:
Assignee:
UNIV ZHEJIANG (CN)
International Classes:
A61K31/704; A61K36/258; A61P7/00; A61P35/00
Foreign References:
| CN109999099A | 2019-07-12 |
Other References:
LI XUE, ZHANG YAN, HONG ZHUPING, GONG SHUQING, LIU WEI, ZHOU XIANGSHAN, SUN YANGEN, QIAN JING, QU HAIBIN: "Transcriptome Profiling Analysis Reveals the Potential Mechanisms of Three Bioactive Ingredients of Fufang E’jiao Jiang During Chemotherapy-Induced Myelosuppression in Mice", FRONTIERS IN PHARMACOLOGY, vol. 9, no. 616, pages 1 - 14, XP093014113, DOI: 10.3389/fphar.2018.00616
Attorney, Agent or Firm:
CHENGDU ZHENGHUA PATENT AGENCY (CN)
Download PDF: